文献速递糖尿病肥胖与代谢综合征

Roux-en-Y胃旁路术对2型糖尿病缓解及并发症的影响:丹麦人群匹配队列研究

Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study.
PubMed 文献 · Diabetologia · 2019-02-06

基于丹麦北部人群的匹配队列研究,纳入1111例接受RYGB的2型糖尿病肥胖患者和1074例匹配非手术患者。随访1年时74%获得糖尿病缓解,5年时27%复发。调整后RYGB组微血管并发症风险降低47%(HR 0.53,95%CI 0.38-0.73),大血管并发症风险降低24%但无统计学意义(HR 0.76,95%CI 0.49-1.18)。

要点

  • RYGB术后1年糖尿病缓解率74%,5年复发率27%
  • 年龄>50岁、糖尿病病程>5年、非二甲双胍用药及基线HbA1c>53mmol/mol预示不缓解
  • RYGB显著降低微血管并发症风险,早期缓解是降低微血管并发症的预测因素

核心结论

  • 在常规临床实践中,RYGB术后1年四分之三的2型糖尿病肥胖患者获得糖尿病缓解,但5年随访时27%复发。
  • RYGB与微血管并发症风险显著降低相关,大血管并发症风险降低但无统计学意义,早期糖尿病缓解是微血管并发症减少的明确预测因素。

研究设计与样本

  • 基于丹麦北部医院2006-2015年的人群队列研究,纳入1111例接受RYGB的2型糖尿病肥胖(BMI>35 kg/m2)患者和1074例匹配的非手术2型糖尿病患者。
  • 糖尿病缓解定义为未使用降糖药且HbA1c<48 mmol/mol(<6.5%),或二甲双胍单药治疗且HbA1c<42 mmol/mol(<6.0%)。
  • 并发症数据来自医疗登记系统,随访完整;采用调整Cox回归比较,随访5.3年。

主要发现

  • RYGB组随访1年时74%获得糖尿病缓解,5年时27%复发。
  • 不缓解的预测因素包括年龄>50岁、糖尿病病程>5年、使用二甲双胍以外的降糖药、基线HbA1c>53 mmol/mol(>7.0%)。
  • 与匹配非手术组相比,RYGB组微血管并发症风险降低47%(HR 0.53,95%CI 0.38-0.73),大血管并发症风险降低24%但无统计学意义(HR 0.76,95%CI 0.49-1.18)。
  • 1年时糖尿病缓解 vs 未缓解与微血管并发症风险降低相关(HR 0.43,95%CI 0.25-0.72),大血管并发症HR 0.76(95%CI 0.40-1.45)。

关键数值与推荐

  • 糖尿病缓解定义:未使用降糖药且HbA1c<48 mmol/mol(<6.5%),或二甲双胍单药且HbA1c<42 mmol/mol(<6.0%)。
  • 不缓解预测因素:年龄>50岁、糖尿病病程>5年、使用二甲双胍以外降糖药、基线HbA1c>53 mmol/mol(>7.0%)。
  • 微血管并发症HR 0.53(95%CI 0.38-0.73),大血管并发症HR 0.76(95%CI 0.49-1.18)。
  • 1年缓解 vs 未缓解:微血管并发症HR 0.43(95%CI 0.25-0.72),大血管并发症HR 0.76(95%CI 0.40-1.45)。

临床怎么用

  • 对2型糖尿病合并肥胖(BMI>35 kg/m2)患者,RYGB可作为一种考虑用于实现糖尿病缓解和降低微血管并发症风险的干预措施。
  • 术前评估应关注年龄、糖尿病病程、降糖药使用情况及基线HbA1c,以预测缓解可能性。
  • 术后需长期随访监测糖尿病复发及并发症,尤其5年内复发风险仍存在。

局限性

  • 观察性匹配队列设计可能存在残余混杂。
  • 大血管并发症风险降低无统计学意义。
  • 研究人群为丹麦北部特定区域,外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: The aim of this study was to examine the effect of Roux-en-Y gastric bypass (RYGB) surgery on diabetes remission, subsequent diabetes relapse and micro- and macrovascular complications in individuals with type 2 diabetes and obesity (BMI >35 kg/m2) in a real-world setting. METHODS: This was a population-based cohort study of 1111 individuals with type 2 diabetes treated by RYGB at hospitals in Northern Denmark (2006-2015), and 1074 matched non-operated individuals with type 2 diabetes. Diabetes remission was defined as no glucose-lowering drug use with HbA1c <48 mmol/mol (<6.5%), or metformin monotherapy with HbA1c <42 mmol/mol (<6.0%). Data on complications were ascertained from medical registries with complete follow-up. RESULTS: At 1 year of follow-up, 74% of the cohort treated by RYGB experienced diabetes remission, while 27% had relapsed after 5 years. Predictors of non-remission were age >50 years, diabetes duration >5 years, use of glucose-lowering drugs other than metformin, and baseline HbA1c >53 mmol/mol (>7.0%). Compared with the non-operated cohort using adjusted Cox regression (5.3 years follow-up), the cohort treated by RYGB had 47% lower risk of microvascular complications (HR 0.53 [95% CI 0.38, 0.73]) and a statistically non-significant 24% lower risk of macrovascular complications (HR 0.76 [95% CI 0.49, 1.18]). Diabetes remission vs non-remission at 1 year was associated with reduced HR of 0.43 (95% CI 0.25, 0.72) for microvascular complications and with HR of 0.76 (95% CI 0.40, 1.45) for macrovascular complications. CONCLUSIONS/INTERPRETATION: In routine clinical care, three out of four individuals with type 2 diabetes and obesity treated by RYGB experienced diabetes remission after 1 year, whereas 27% of these individuals had relapsed at 5 years follow-up. RYGB was associated with substantially decreased risk of microvascular complications and non-significantly fewer macrovascular complications, with early diabetes remission as a clear predictor of reduced microvascular complications.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Madsen LR, Baggesen LM, Richelsen B, et al. Effect of Roux-en-Y gastric bypass surgery on diabetes remission and complications in individuals with type 2 diabetes: a Danish population-based matched cohort study. Diabetologia. 2019. PMID: 30734055. doi:10.1007/s00125-019-4816-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。